subject: Global Top 10 Healthcare Equipment Companies - Industry, Financial And Swot Analysis [print this page] Introduction Introduction
Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle class and private sector have turned countries like Brazil, Russia or India into a promising commercial opportunity.
Scope
*Analysis of current HIV market dynamics across Brazil, Russia and India
*Thorough assessment of underlying commercial and clinical factors, opportunities and threats shaping the antiretroviral market in these regions
*Review of sales trends and brand dynamics of key branded and generic agents
*Discussion of key domestic HIV drug makers as well as the position of major international players
Highlights
Brazil has one of most successful treatment programs for HIV-infected individuals, providing free access to HIV prevention and care. Despite challenges for international HIV drug makers arising from local competitors and compulsory licensing, growing concerns over drug resistance and intolerance are creating new revenue opportunities.
In Russia, HIV remained a low priority issue for several years but the situation has recently improved and the level of funding for treatment has increased. Given the lower level of generic incursion, there is significant opportunity for branded drugs due to the size of the epidemic, particularly as patients progress to late stage therapy.
Although the Indian HIV market is highly genericized, the introduction of the 2005 Patent Act could lead to improvements in intellectual property protection for global companies with branded products, illustrated by recent approvals for the patents of Selzentry, Isentress and Intelence in India.
Reasons to Purchase
*Identify key opportunities that will impact the use and uptake of new and existing HIV antiretrovirals
*Gain insight into the market environment for HIV antiretrovirals through a review of demographic, economic, regulatory and treatment trends
*Gain competitive advantage by identifying key HIV players, product characteristics and potential roles for new therapies
Table of Contents :
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Infectious Diseases pharmaceutical analysis team 2
Executive Summary 3
Scope of the analysis 3
Datamonitor insight into the HIV market 3
Related reports 6
Upcoming reports 6
Table of Contents 7
1. Brazil 7
Key findings 7
General characteristics 8
Demographics 8
Economics 10
Healthcare expenditure and access 11
Regulatory procedures 14
Drug approval process 14
New drug approvals must be registered with ANVISA 14
Imported pharmaceuticals have to be registered with ANVISA 15
Drug pricing 15
Pricing of new drugs is controlled by the CMED 15
Prices of marketed pharmaceuticals are controlled through price freezes and increases 16
Intellectual property protection 17
The HIV market in Brazil 17
Epidemiological trends 17
Current market situation 19
Historic development and access to antiretroviral therapy 25
Treatment guidelines and recommendations 26
Opportunities 28
Increase in number of patients accessing treatment 28
Resistance and intolerance creates a need for novel therapies 29
Increased financing for novel antiretroviral drugs 29
Threats 31
The threat of compulsory licensing reduces the attractiveness of the Brazilian market 31
Growing cost pressures may lead to a cut in the medication budget 32
Key HIV players in Brazil 32
General overview 32
Multinational corporations 35
Local manufacturers 36
Farmanguinhos 36
Blausiegel 37
Key conclusions for Brazil 37
2. Russia 38
Key findings 38
General characteristics 39
Demographics 39
Economics 41
Healthcare expenditure and access 42
Regulatory procedures 45
Drug approval process 45
Drug pricing 46
Intellectual property protection 47
The HIV market in Russia 47
Epidemiological trends 47
Current market situation 51
Historic development and access to antiretroviral therapy 54
Treatment guidelines and recommendations 56
Opportunities and threats 57
Opportunities 57
Level of funding for HIV programs has increased 57
The Russian market is dominated by branded antiretrovirals 57
Threats 58
Stigma associated with HIV infection restricts the number of patients accessing therapy 58
There is an increasing pressure on pharmaceutical companies to reduce antiretroviral prices 59
Key HIV players in the Russian Federation 60
General overview 60
Multinational corporations 61
GlaxoSmithKline dominates the Russian antiretrovirals market 61
Tibotec has strengthened its presence in the Russian market 62
Local manufacturers 62
Key conclusions for Russia 63
3. India 64
Key findings 64
General characteristics 65
Demographics 65
Economics 67
Healthcare expenditure and access 68
Regulatory procedures 70
Drug approval process 71
Drug pricing 71
Intellectual property protection 72
The HIV market in India 72
Epidemiological trends 72
Current market overview 74
Historic development and access to antiretroviral therapy 79
Treatment guidelines 82
First-line therapy recommendations 82
Recommendations for switching therapy due to intolerance or treatment failure 83
Opportunities and threats 84
Opportunities 84
Patents granted for Selzentry, Isentress and Intelence indicating a potential shift in IP environment 84
Voluntary licenses and patent pooling 84
Growing need for second-line treatment 85
Threats 86
Low treatment coverage rates 86
India is benefiting from compulsory licenses for HIV/AIDS drugs in other countries 86
